ProMIS Neurosciences is trading 5.62% down at $10.24, with no confirmed company-specific catalyst identified for October 1, 2026. - The company announced October conference participation on September 30, including the H.C. Wainwright Biotech On Tap event; the announcement does not establish a reason for the decline. - Major indices are modestly lower, without a move exceeding 0.5% to clearly explain the stock’s drop.